-
公开(公告)号:NO20076616L
公开(公告)日:2008-02-01
申请号:NO20076616
申请日:2007-12-21
Applicant: SOLVAY PHARM GMBH
Inventor: MESSINGER JOSEF , WESKE MICHAEL , KOSKIMIES PASI , THOLE HEINRICH-HUBERT , HUSEN BETTINA , PIRKKALA LILA
IPC: C07J41/00
Abstract: The present invention relates to novel substituted steroid derivatives which represent selectiv inhibitors of the 17ß-hydroxysteroid dehydrogenase type I (17ß-HSD1) and, in addition, which may represent inhibitors of the steroid sulphatase, as well as to their salts, to pharmaceutical preparations containing these compounds and to processes for the preparation of these compounds. Furthermore, the invention concerns the therapeutic use of said novel substituted steroid derivatives, particularly their use in the treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of 17ß-hydroxysteroid dehydrogenase type I and/or steroid sulphatase enzymes and/or requiring the lowering of the endogenous 17ß-estradiol concentration.
-
公开(公告)号:NO20075766A
公开(公告)日:2007-11-09
申请号:NO20075766
申请日:2007-11-09
Applicant: SOLVAY PHARM GMBH
Inventor: ZIEGLER DIETER , WESKE MICHAEL , FISCHER YVAN , MOLONEY BRIAN , MARRISON LESTER , MLINARIC MICHAEL , BOECKER CHRISTIANE , BRUECKNER REINHARD , WITTE KLAUS
IPC: C07D311/68 , C07D405/12
CPC classification number: C07D311/68 , C07D405/12 , C07D413/12
-
公开(公告)号:CA2609726A1
公开(公告)日:2006-11-30
申请号:CA2609726
申请日:2006-05-24
Applicant: SOLVAY PHARM GMBH
Inventor: HUSEN BETTINA , THOLE HEINRICH-HUBERT , KOSKIMIES PASI , PIRKKALA LILA , MESSINGER JOSEF , WESKE MICHAEL
Abstract: The present invention relates to novel substituted steroid derivatives which represent selectiv inhibitors of the 17ß-hydroxysteroid dehydrogenase type I (17ß-HSD1) and, in addition, which may represent inhibitors of the steroid sulphatase, as well as to their salts, to pharmaceutical preparations containing these compounds and to processes for the preparation of these compounds. Furthermore, the invention concerns the therapeutic use of said novel substituted steroid derivatives, particularly their use in the treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of 17ß-hydroxysteroid dehydrogenase type I and/or steroid sulphatase enzymes and/or requiring the lowering of the endogenous 17ß-estradiol concentration.
-
公开(公告)号:AR045798A1
公开(公告)日:2005-11-16
申请号:ARP040103409
申请日:2004-09-22
Applicant: SOLVAY PHARM GMBH
Inventor: HOLTJE DAGMAR , FISCHER IVAN , ZIEGLER DIETER , WESKE MICHAEL , MICHAELIS KATRIN , MESSINGER JOSEF , PAHL AXEL , KARIMI-NEJAD YASMIN
IPC: A61K38/00 , A61P9/12 , C07K5/02 , C07K5/078 , C07K5/06 , C07K1/06 , A61K38/05 , A61K31/55 , A61P9/00 , A61P15/00 , A61P25/28
Abstract: Se describen compuestos con actividad inhibidora de la endopeptidasa neutra (NEP) y/o la endopeptidasa humana soluble (hSEP), así como medicamentos que contienen estos compuestos, en particular medicamentos adecuados para tratamiento o prevención de enfermedades cardiovasculares, disfunción sexual y/o condiciones adversas asociadas con apoptosis. Reivindicación 1: Compuestos de la fórmula general (1), en donde: R1 es hidrógeno o un grupo formador de un éster biolábil; R2 es hidrógeno, alquilo C1-4 o hidroxialquilo C1-4, cuyo grupo hidroxilo está esterificado opcionalmente con alcanoilo C2-4 o un residuo de aminoácido; y R3 es alquilo C1-4; alcoxi(C1-4)-alquilo(C1-4); hidroxialquilo C1-4, que está sustituido opcionalmente con un segundo grupo hidroxilo y cuyos grupos hidroxilo están esterificados cada uno opcionalmente con alcanoilo C2-4 o un residuo de aminoácido; (alquil C0-4)2amino-alquilo(C1-4); cicloalquilo C3-7; cicloalquil(C3-7)-alquilo(C1-4); fenil-alquilo(C1-4), cuyo grupo fenilo está sustituido opcionalmente 1-2 veces con alquilo C1-4, alcoxi C1-4 y/o halógeno; naftil-alquilo(C1-4); oxoalquilo C3-6; fenilcarbonilmetilo, cuyo grupo fenilo está sustituido opcionalmente 1-2 veces con alquilo C1-4, alcoxi C1-4 y/o halógeno, o 2-oxoazepanilo; o R2 y R3 juntos son alquileno C4-7, cuyos grupos metileno están reemplazados opcionalmente 1-2 veces por carbonilo, nitrógeno, oxígeno y/o azufre, y/o que están sustituidos opcionalmente una sola vez con hidroxi, que está esterificado opcionalmente con alcanoilo C2-4 o un residuo de aminoácido; alquilo C1-4; hidroxialquilo C1-4, cuyo grupo hidroxilo está esterificado opcionalmente con alcanoilo C2-4 o un residuo de aminoácido; fenilo o bencilo; y R4 es hidrógeno o un grupo formador de un éster biolábil, y sales fisiológicamente compatibles de los ácidos de fórmula (1) y/o sales de adición de ácido fisiológicamente compatibles de los compuestos de fórmula (1).
-
公开(公告)号:AU2004281195A1
公开(公告)日:2005-04-28
申请号:AU2004281195
申请日:2004-10-14
Applicant: SOLVAY PHARM GMBH
Inventor: MOLONEY BRIAN , WESKE MICHAEL , SYKES DAVID , FISCHER YVAN , MLINARIC MICHAEL , BOECKER CHRISTIANE , BRUECKNER REINHARD , WITTE KLAUS , MARRISON LESTER , ZIEGLER DIETER
IPC: A61K31/353 , C07D311/68 , C07D407/12
Abstract: The invention relates to compounds of general formula (I), wherein the meaning of R 1 , R 2 , R 3 , R 4 , R 5 and R 6 is given in a description, to a method for producing said compounds and to intermediate products thereof. Drugs containing the inventive compounds of formula (1) are also disclosed.
-
公开(公告)号:AU2004276002A1
公开(公告)日:2005-04-07
申请号:AU2004276002
申请日:2004-09-23
Applicant: SOLVAY PHARM GMBH
Inventor: HOELTJE DAGMAR , ZIEGLER DIETER , MICHAELIS KATHRIN , PAHL AXEL , MESSINGER JOSEF , WESKE MICHAEL , TURSKI LECHOSLAW , HOEFER CONSTANZE , FISCHER YVAN , KARIMI-NEJAD YASMIN , IKONOMIDOU HRISSANTHI
Abstract: Described are novel compounds with neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity of the general formula (I), wherein the substituents R , R , R and R have the meanings given in the description and also medicaments containing these compounds, in particular medicaments suitable for treating or preventing cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.
-
37.
公开(公告)号:NZ523960A
公开(公告)日:2004-12-24
申请号:NZ52396001
申请日:2001-07-12
Applicant: SOLVAY PHARM GMBH
Inventor: ANTEL JOCHEN , PREUSCHOFF ULF , DAVID SAMUEL , WESKE MICHAEL , HEBEBRAND JOHANNES
Abstract: Compounds for the treatment and/or prevention of obesity are selected on the basis of their capability to inhibit de novo lipogenesis in mammals. An independent claim is also included for the use of compounds which are capable of inhibiting de novo lipogenesis in mammals and which have no anticonvulsant activity for the production of a medicament for the treatment and/or prevention of obesity. - ACTIVITY : Anorectic. - MECHANISM OF ACTION : Lipogenesis inhibitor; Carboanhydrase inhibitor. No biological data given.
-
38.
公开(公告)号:ZA200300444B
公开(公告)日:2004-04-16
申请号:ZA200300444
申请日:2003-01-16
Applicant: SOLVAY PHARM GMBH
Inventor: JOHANNES HEBEBRAND , ULF ANTEL JOCHEN PREUSCHOFF , DAVID SAMUEL , SANN HOLGER , WESKE MICHAEL
IPC: F16D27/112 , A61P , G01N
-
公开(公告)号:NO20030233L
公开(公告)日:2003-03-19
申请号:NO20030233
申请日:2003-01-17
Applicant: SOLVAY PHARM GMBH
Inventor: HEBEBRAND JOHANNES , ANTEL JOCHEN , PREUSCHOFF ULF , DAVID SAMUEL , SANN HOLGER , WESKE MICHAEL
IPC: G01N33/50 , A61K45/00 , A61P1/00 , A61P3/04 , C12Q1/02 , C12Q1/527 , G01N33/15 , C12Q1/34 , G01N33/68 , A61P3/06
Abstract: Compounds for the treatment and/or prevention of obesity are selected on the basis of their capability to inhibit de novo lipogenesis in mammals. An independent claim is also included for the use of compounds which are capable of inhibiting de novo lipogenesis in mammals and which have no anticonvulsant activity for the production of a medicament for the treatment and/or prevention of obesity. - ACTIVITY : Anorectic. - MECHANISM OF ACTION : Lipogenesis inhibitor; Carboanhydrase inhibitor. No biological data given.
-
公开(公告)号:NO20030233D0
公开(公告)日:2003-01-17
申请号:NO20030233
申请日:2003-01-17
Applicant: SOLVAY PHARM GMBH
Inventor: HEBEBRAND JOHANNES , ANTEL JOCHEN , PREUSCHOFF ULF , DAVID SAMUEL , SANN HOLGER , WESKE MICHAEL
Abstract: Compounds for the treatment and/or prevention of obesity are selected on the basis of their capability to inhibit de novo lipogenesis in mammals. An independent claim is also included for the use of compounds which are capable of inhibiting de novo lipogenesis in mammals and which have no anticonvulsant activity for the production of a medicament for the treatment and/or prevention of obesity. - ACTIVITY : Anorectic. - MECHANISM OF ACTION : Lipogenesis inhibitor; Carboanhydrase inhibitor. No biological data given.
-
-
-
-
-
-
-
-
-